Pharma

Taking stock of the drug industry, from the lab to the medicine chest. For a weekly update, sign up for our free Pharmalot newsletter. And subscribe to STAT+ for exclusive coverage and analysis of the pharma industry — from drug pipelines to boardroom shakeups.

Pharmalot Damian Garde

Pharmalittle: Democrats concede on passing ‘clean’ FDA funding bill; Biogen whistleblower nets $250 million

Biogen finalized a $900 million kickback settlement with the U.S. Justice Department, and nearly $250 million will go to a whistleblower.

Read The Story

First Opinion Adam C. Urato

FDA: Ignore a pharma company’s deceptive racial equity argument for keeping Makena, an ineffective preterm labor drug

First Opinion Aoife Brennan

Subject, not suspect: The new hazards of conducting clinical research in the Dobbs era

Pharmalot Ed Silverman

Inflation caused another big drop in net drug prices, analysis finds

First Opinion Jeff Baldetti

Market share isn’t the only metric for biosimilars’ success

All Coverage

Exclusive Rachel Cohrs

Medicare lays out the bureaucracy it will need to negotiate drug prices

Pharmalot Ed Silverman

Pharmalittle: Biogen Alzheimer’s drug slowed cognitive decline in a trial; European pharma warns energy costs may halt some generic production

Pharmalot Ed Silverman

Lilly is accused by the federal government of discriminating against older sales reps

Pharmalot Damian Garde

Pharmalittle: GSK picks its first female CFO; Pfizer advances Omicron booster for kids

Pharmalot Ed Silverman

Some European regulators are starting to take steps to ensure clinical trial results are reported

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

Pharmalittle: U.S. drug net prices fell nearly 8% in the second quarter; FDA panel favors fecal-based therapy for bacterial infections

Pharmalot Ed Silverman

Solicitor general recommends Supreme Court shouldn’t review an Amgen patent case

Pharmalot Ed Silverman

Pharmalittle: Biogen ALS drug trial yields mixed signals; Novartis makes U.S. growth its top priority

Pharmalot Ed Silverman

Pharmalittle: FDA scolds Catalent over quality control at plant making Covid shots; Novartis will ask SCOTUS to protect a key patent

Pharmalot Ed Silverman

Catalent is scolded by FDA for quality control issues at a plant that helps make Covid-19 vaccines

Pharmalot Ed Silverman

Pharmalittle: Haleon argues it’s not liable for any Zantac claims; FDA steps up surprise inspections in India

Politics Ambar Castillo

House Democrat presses bill to encourage more diversity in clinical trials run by NIH

Pharmalot Ed Silverman

Pfizer accused of running a fellowship program that discriminates on racial grounds

Pharmalot Ed Silverman

Pharmalittle: Advances in treating the sickest Covid patients have stalled; Moderna aids WHO effort to develop mRNA coronavirus shots

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

Pharmalittle: CRISPR-based drug shows promise in preliminary study; FDA user fee program prompts fresh worries over conflicts

Pharmalot Ed Silverman

Brazil dismisses antitrust complaint against Gilead over pricing for a hepatitis C drug

Pharmalot Ed Silverman

Pharmalittle: Swiss authorities probe Novartis over patent used to block rivals; Medicare underserves older Americans with opioid use disorder

Pharmalot Ed Silverman

Swiss authorities raid Novartis offices seeking info on patents used to block rivals

Pharmalot Ed Silverman

Pharmalittle: Pharma pursues the ‘dream’ of online prescribing; EC chief under fire over Pfizer vaccine contract

Pharmalot Ed Silverman

Pharmalittle: Biden picks biotech exec to lead new biomedical research agency; FDA to hold meeting for OTC birth control pill

Pharmalot Ed Silverman

Pharmalittle: FDA approves new type of psoriasis drug; U.S. starts late-stage trial to test an antiviral against monkeypox

Pharmalot Ed Silverman

Pharma

Pharmalittle: Democrats concede on passing ‘clean’ FDA funding bill; Biogen whistleblower nets $250 million

FDA: Ignore a pharma company’s deceptive racial equity argument for keeping Makena, an ineffective preterm labor drug

Subject, not suspect: The new hazards of conducting clinical research in the Dobbs era

Inflation caused another big drop in net drug prices, analysis finds

Market share isn’t the only metric for biosimilars’ success

All Coverage

Medicare lays out the bureaucracy it will need to negotiate drug prices

Pharmalittle: Biogen Alzheimer’s drug slowed cognitive decline in a trial; European pharma warns energy costs may halt some generic production

Lilly is accused by the federal government of discriminating against older sales reps

Pharmalittle: GSK picks its first female CFO; Pfizer advances Omicron booster for kids

Some European regulators are starting to take steps to ensure clinical trial results are reported

Up and down the ladder: The latest comings and goings

Pharmalittle: U.S. drug net prices fell nearly 8% in the second quarter; FDA panel favors fecal-based therapy for bacterial infections

Solicitor general recommends Supreme Court shouldn’t review an Amgen patent case

Pharmalittle: Biogen ALS drug trial yields mixed signals; Novartis makes U.S. growth its top priority

Pharmalittle: FDA scolds Catalent over quality control at plant making Covid shots; Novartis will ask SCOTUS to protect a key patent

Catalent is scolded by FDA for quality control issues at a plant that helps make Covid-19 vaccines

Pharmalittle: Haleon argues it’s not liable for any Zantac claims; FDA steps up surprise inspections in India

House Democrat presses bill to encourage more diversity in clinical trials run by NIH

Pfizer accused of running a fellowship program that discriminates on racial grounds

Pharmalittle: Advances in treating the sickest Covid patients have stalled; Moderna aids WHO effort to develop mRNA coronavirus shots

Up and down the ladder: The latest comings and goings

Pharmalittle: CRISPR-based drug shows promise in preliminary study; FDA user fee program prompts fresh worries over conflicts

Brazil dismisses antitrust complaint against Gilead over pricing for a hepatitis C drug

Pharmalittle: Swiss authorities probe Novartis over patent used to block rivals; Medicare underserves older Americans with opioid use disorder

Swiss authorities raid Novartis offices seeking info on patents used to block rivals

Pharmalittle: Pharma pursues the ‘dream’ of online prescribing; EC chief under fire over Pfizer vaccine contract

Pharmalittle: Biden picks biotech exec to lead new biomedical research agency; FDA to hold meeting for OTC birth control pill

Pharmalittle: FDA approves new type of psoriasis drug; U.S. starts late-stage trial to test an antiviral against monkeypox

USDA starts cracking down on companies that ship animals without timely inspections

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day